Author(s): Funnell MM, Kruger DF
Abstract Share this page
Abstract Traditionally, practitioners have reserved insulin therapy for patients with type 2 diabetes until diet, exercise, and treatment with oral agents have failed to maintain glycemic control. Increasing evidence, however, supports advancing insulin therapy earlier in treating diabetes, not only to normalize glycemic control and emulate normal physiologic insulin secretion, but also to delay or prevent disease-associated comorbidity.
This article was published in Nurse Pract
and referenced in Journal of Bioequivalence & Bioavailability